Ushering in the study and treatment of preclinical Alzheimer disease

Jessica B. Langbaum, Adam S. Fleisher, Kewei Chen, Napatkamon Ayutyanont, Francisco Lopera, Yakeel T. Quiroz, Richard John Caselli, Pierre N. Tariot, Eric M. Reiman

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.

Original languageEnglish (US)
Pages (from-to)371-381
Number of pages11
JournalNature Reviews Neurology
Volume9
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Alzheimer Disease
Biological Phenomena
Research
Neuroimaging
Cerebrospinal Fluid
Dementia
Biomarkers
Research Personnel

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Langbaum, J. B., Fleisher, A. S., Chen, K., Ayutyanont, N., Lopera, F., Quiroz, Y. T., ... Reiman, E. M. (2013). Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 9(7), 371-381. https://doi.org/10.1038/nrneurol.2013.107

Ushering in the study and treatment of preclinical Alzheimer disease. / Langbaum, Jessica B.; Fleisher, Adam S.; Chen, Kewei; Ayutyanont, Napatkamon; Lopera, Francisco; Quiroz, Yakeel T.; Caselli, Richard John; Tariot, Pierre N.; Reiman, Eric M.

In: Nature Reviews Neurology, Vol. 9, No. 7, 07.2013, p. 371-381.

Research output: Contribution to journalArticle

Langbaum, JB, Fleisher, AS, Chen, K, Ayutyanont, N, Lopera, F, Quiroz, YT, Caselli, RJ, Tariot, PN & Reiman, EM 2013, 'Ushering in the study and treatment of preclinical Alzheimer disease', Nature Reviews Neurology, vol. 9, no. 7, pp. 371-381. https://doi.org/10.1038/nrneurol.2013.107
Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology. 2013 Jul;9(7):371-381. https://doi.org/10.1038/nrneurol.2013.107
Langbaum, Jessica B. ; Fleisher, Adam S. ; Chen, Kewei ; Ayutyanont, Napatkamon ; Lopera, Francisco ; Quiroz, Yakeel T. ; Caselli, Richard John ; Tariot, Pierre N. ; Reiman, Eric M. / Ushering in the study and treatment of preclinical Alzheimer disease. In: Nature Reviews Neurology. 2013 ; Vol. 9, No. 7. pp. 371-381.
@article{cb6e16908d4c44d99b1a4c6f67c9d948,
title = "Ushering in the study and treatment of preclinical Alzheimer disease",
abstract = "Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.",
author = "Langbaum, {Jessica B.} and Fleisher, {Adam S.} and Kewei Chen and Napatkamon Ayutyanont and Francisco Lopera and Quiroz, {Yakeel T.} and Caselli, {Richard John} and Tariot, {Pierre N.} and Reiman, {Eric M.}",
year = "2013",
month = "7",
doi = "10.1038/nrneurol.2013.107",
language = "English (US)",
volume = "9",
pages = "371--381",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Ushering in the study and treatment of preclinical Alzheimer disease

AU - Langbaum, Jessica B.

AU - Fleisher, Adam S.

AU - Chen, Kewei

AU - Ayutyanont, Napatkamon

AU - Lopera, Francisco

AU - Quiroz, Yakeel T.

AU - Caselli, Richard John

AU - Tariot, Pierre N.

AU - Reiman, Eric M.

PY - 2013/7

Y1 - 2013/7

N2 - Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.

AB - Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.

UR - http://www.scopus.com/inward/record.url?scp=84881478550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881478550&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2013.107

DO - 10.1038/nrneurol.2013.107

M3 - Article

C2 - 23752908

AN - SCOPUS:84881478550

VL - 9

SP - 371

EP - 381

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 7

ER -